advertisement
Emerging Options in Osteoporosis
Share
Save
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Recommended
Details
Presenters
Overview
Dr. Murray Favus, a Professor of Medicine at The University of Chicago Pritzker School of Medicine, and director of The University of Chicago Bone Program discusses denosumab, zoledronic acid, oral calcium sensing receptor antagonists, and other emerging therapies for osteoporosis.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?